Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px

Product › Details

Lumevoq®

	Next higher product group	lenadogene nolparvovec (GS010)
	Status	2020-10-22 registration pending
	Organisation	GenSight Biologics S.A. (Euronext: SIGHT)
	Source	GenSight Biologics S.A.. (10/22/20). "Press Release: GenSight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With US and European Institutional Investors". Paris.

Record changed: 2024-02-12

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for lenadogene nolparvovec (GS010)

[1] GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris....
[2] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
[3] GenSight Biologics S.A.. (4/3/18). "Press Release: GenSight Biologics Announces Topline Results from REVERSE Phase III Clinical Trial of GS010 in Patients with Leber Hereditary Optic Neuropathy (LHON)". Paris....
[4] GenSight Biologics S.A.. (8/1/17). "Press Relase: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy". Paris....
[5] GenSight Biologics S.A.. (6/23/17). "Press Release: GenSight Biologics Successfully Raises €22.5 Million from Leading Investors in the US and Europe [Not for distribution in Canada, Australia and Japan]". Paris....
[6] Reuters. (6/23/17). "News: BRIEF – Gensight Biologics Raises 22.5 Million Euros"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]